SMAD4 and familial pancreatic carcinoma: In summary, this study provides mechanistic evidence for a tumorigenic role of miR-552 in pancreatic cancer and uncovers a novel FOXM1-miR-552-DACH1/PCDH10/SMAD4 axis that promotes pancreatic cancer progression.